A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Nemtabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms BELLWAVE-003; MK-1026-003
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 29 May 2024 Planned number of patients changed from 450 to 490.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 27 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended as change in timeframe for primary end point is from 78months to 34 months.